GlaxoSmithKline – Q1 update, still further share price upside as demerger nears
GlaxoSmithKline (GSK) has announced its first quarter of the year results and that it reconfirms its full-year 2022 guidance. We are well ahead on this share tip where we are also drinking our own medicine so what to do now?
- By Tom Winnifrith and Steve Moore
- 2022-05-02 20:09:00